2 assets in Major Salivary Gland Cancer

Therapeutic assets addressing Major Salivary Gland Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ceralasertib Major Salivary Gland Cancer	National Cancer Institute (NCI)	P1	CC (43)
Trastuzumab Deruxtecan Major Salivary Gland Cancer	National Cancer Institute (NCI)	P1	CC (43)